Draft:Viking Therapeutics
| Submission declined on 30 October 2024 by S0091 (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
 | This is a draft article. It is a work in progress open to editing by anyone. Please ensure core content policies are met before publishing it as a live Wikipedia article. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Last edited by Citation bot (talk | contribs) 2 seconds ago. (Update)
Finished drafting? or |
Viking Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, CA, and founded on September 24, 2012, by Brian Lian, Ph.D., and Michael Dinerman, M.D. The company develops therapies for metabolic and endocrine disorders, such as obesity, diabetes, and non-alcoholic steatohepatitis (NASH).[1].[2]
Viking Therapeutics gained popularity with Wall Street investors[3], after positive phase 1 trials for an oral form of a dual GLP-1/GIP (VK2735) agonist aimed at treating obesity[4][5]
In addition to the above, Viking Therapeutics has two other pharmaceutical therapeutics in the pipeline. These are VK0214, developed to treat X-linked adrenoleukodystrophy, and VK2809 developed to treat non-alcoholic steatohepatitis and fibrosis.[6]
- ^ https://www.wsj.com/market-data/quotes/VKTX/company-people#:~:text=Viking%20Therapeutics%2C%20Inc.%20is%20a,headquartered%20in%20San%20Diego%2C%20CA.
- ^ "Ex-99.1".
- ^ "Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?". 26 August 2024.
- ^ "Viking Therapeutics Reveals Positive Results from Oral Obesity Drug". 26 March 2024.
- ^ https://clinicaltrials.gov/study/NCT06068946#study-plan
- ^ "Pipeline Overview".
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.